Mycobacterial and Other Serious Infections in Patients Receiving Anti–Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network | Zendy

Kevin Winthrop | Zendy; S. Yamashita | Zendy; Susan E. Beekmann | Zendy; Philip M. Polgreen | Zendy

Open Access

Mycobacterial and Other Serious Infections in Patients Receiving Anti–Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network

Author(s) -

Kevin Winthrop,

S. Yamashita,

Susan E. Beekmann,

Philip M. Polgreen

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/587989

Subject(s) - medicine , tuberculosis , histoplasmosis , context (archaeology) , staphylococcus aureus , immunology , nontuberculous mycobacteria , disease , tumor necrosis factor alpha , intensive care medicine , mycobacterium , pathology , paleontology , genetics , bacteria , biology

We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research